denotes an abstract that is clinically relevant.
denotes that this is a ticketed session.
Description:
Considered the original form of cell therapy, the field of stem cell transplantation has undergone a paradigm shift since Dr. Don Thomas’ seminal publication in 1957. Advances in our basic understanding of the graft-versus-leukemia effect have paved the way for novel engineered cell-based therapeutics with target antigen specificity and without the toxicity associated with graft-versus-host disease. In this session we will provide an overview of the past, present and future of this exciting field.
Dr. Stephan Mielke will provide a historical overview of the evolution of allogeneic stem cell transplantation and emerging cell therapies, such as CAR T cells from experimental therapies to standard of care. He will present data to support the role of immunotherapy, both as a definitive treatment approach as well as a complement to allogeneic stem cell transplantation in the context of different malignancies. He will challenge the definitions of clinical success from the perspectives of regulatory hurdles, value-based healthcare and patient access to treatment.
Dr. Jesus G. Berdeja will discuss the unique safety profile and logistical aspects that pose challenges and opportunities for the safe and successful delivery of these therapies. Close interaction, communication, and established partnerships between the community practitioner, the disease specialist and the transplant physician will be required to provide the optimal care longitudinally for any one patient. Dr. Berdeja will discuss practical aspects for programs to deliver these therapies and how future advances may ultimately widen availability beyond just a few centers.
Dr. Katayoun Rezvani will provide an overview of next-generation cell therapies beyond T cells, including the application of natural killer (NK) cells, invariant NKT cells, macrophages and other immune subsets as platforms for CAR engineering. She will also discuss the application of gene editing technologies such as CRISPR-Cas9 to further enhance the safety and potency of engineered cells for the immunotherapy of cancer.
Dr. Stephan Mielke will provide a historical overview of the evolution of allogeneic stem cell transplantation and emerging cell therapies, such as CAR T cells from experimental therapies to standard of care. He will present data to support the role of immunotherapy, both as a definitive treatment approach as well as a complement to allogeneic stem cell transplantation in the context of different malignancies. He will challenge the definitions of clinical success from the perspectives of regulatory hurdles, value-based healthcare and patient access to treatment.
Dr. Jesus G. Berdeja will discuss the unique safety profile and logistical aspects that pose challenges and opportunities for the safe and successful delivery of these therapies. Close interaction, communication, and established partnerships between the community practitioner, the disease specialist and the transplant physician will be required to provide the optimal care longitudinally for any one patient. Dr. Berdeja will discuss practical aspects for programs to deliver these therapies and how future advances may ultimately widen availability beyond just a few centers.
Dr. Katayoun Rezvani will provide an overview of next-generation cell therapies beyond T cells, including the application of natural killer (NK) cells, invariant NKT cells, macrophages and other immune subsets as platforms for CAR engineering. She will also discuss the application of gene editing technologies such as CRISPR-Cas9 to further enhance the safety and potency of engineered cells for the immunotherapy of cancer.